ReviewIbrain2025
Epigenetic regulation in cognitive impairment: Focus on N6-methyladenosine modification and its potential role in perioperative neurocognitive disorders.
Review in Ibrain, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Regulatory mechanisms and therapeutic potential of N6-methyladenosine modification in retinal diseases (Review).Molecular medicine reports · 2026Review
- The role of epigenetic modifications in cancer-associated fibroblasts.Frontiers in medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
N6-methyladenosine (m6A), the most abundant internal modification in mammalian mRNA, plays a critical role in cognitive function by dynamically regulating gene expression. This narrative review examines m6A's role in cognitive processes and its potential impact on perioperative neurocognitive disorders (PNDs), which encompass a spectrum including postoperative delirium, delayed neurocognitive recovery, and postoperative cognitive dysfunction. The m6A regulatory machinery-comprising methyltransferases ("writers"), demethylases ("erasers"), and recognition proteins ("readers")-modulates neuronal development, synaptic plasticity, and cognitive processes by influencing mRNA stability, translation, and degradation. Evidence from animal models indicates that m6A dysregulation contributes to neuroinflammation, neurodegeneration, and neuronal injury, which are pathophysiological mechanisms implicated in PNDs. Notably, anesthetic agents and surgical stress have been shown to alter hippocampal m6A levels, and manipulation of m6A-related proteins may ameliorate cognitive deficits. While these findings suggest potential mechanistic connections, direct evidence specifically linking m6A modifications to PNDs pathogenesis remains preliminary and largely based on preclinical models. Further research is needed to establish causal relationships, identify m6A-modified targets relevant to PNDs pathology, and evaluate m6A as a potential biomarker or therapeutic target. This review provides a foundation for understanding how m6A modification may influence perioperative cognitive outcomes and identifies promising avenues for future investigation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.